Aytu BioPharma GAAP EPS of -$2.93 misses by $2.88, revenue of $15.1M misses by $2.82M

* Aytu BioPharma press release [https://seekingalpha.com/pr/20242010-aytu-biopharma-reports-fiscal-2025-full-year-and-fourth-quarter-operational-and-financial] (NASDAQ:AYTU [https://seekingalpha.com/symbol/AYTU]): Q4 GAAP EPS of -$2.93 misses by $2.88.
* Revenue of $15.1M misses by $2.82M.
*
Full Year Fiscal 2025 Highlights

●

Net revenue increased 2% to $66.4 million versus $65.2 million in fiscal 2024.

●

ADHD Portfolio (primarily Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue was $57.6 million versus $57.8 million in fiscal 2024.

●

Pediatric Portfolio (primarily Karbinal® ER, Poly-Vi-Flor® and Tri-Vi-Flor®) net revenue was $8.8 million versus $7.3 million in fiscal 2024.

●

Net loss of $13.6 million compared to a net loss of $15.8 million. Net loss in fiscal 2025 included $12.1 million of combined impairment expense, restructuring costs and derivative warrant liabilities loss.

●

Adjusted EBITDA was $9.2 million compared to $10.8 million in fiscal 2024.

●

Cash and cash equivalents were $31.0 million at June 30, 2025.

MORE ON AYTU BIOPHARMA

* FDA targets drug marketing, advertising with slew of warning letters [https://seekingalpha.com/news/4495734-fda-targets-drug-marketing-advertising-with-slew-warning-letters]
* Seeking Alpha’s Quant Rating on Aytu BioPharma [https://seekingalpha.com/symbol/AYTU/ratings/quant-ratings]
* Historical earnings data for Aytu BioPharma [https://seekingalpha.com/symbol/AYTU/earnings]
* Financial information for Aytu BioPharma [https://seekingalpha.com/symbol/AYTU/income-statement]